These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38072353)

  • 1. Verteporfin regulates corneal neovascularization through inhibition of YAP protein activation.
    Lin L; Zheng Y; Li Q; Sun Y; Huang Y; Liang L; Xu L; Zhao YE
    Exp Eye Res; 2024 Jan; 238():109747. PubMed ID: 38072353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of YAP ameliorates choroidal neovascularization via inhibiting endothelial cell proliferation.
    Yan Z; Shi H; Zhu R; Li L; Qin B; Kang L; Chen H; Guan H
    Mol Vis; 2018; 24():83-93. PubMed ID: 29422766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2.
    Renno RZ; Terada Y; Haddadin MJ; Michaud NA; Gragoudas ES; Miller JW
    Arch Ophthalmol; 2004 Jul; 122(7):1002-11. PubMed ID: 15249365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinically used photosensitizer Verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation.
    Brodowska K; Al-Moujahed A; Marmalidou A; Meyer Zu Horste M; Cichy J; Miller JW; Gragoudas E; Vavvas DG
    Exp Eye Res; 2014 Jul; 124():67-73. PubMed ID: 24837142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Choroidal neovascularization reduced by targeted drug delivery with cationic liposome-encapsulated paclitaxel or targeted photodynamic therapy with verteporfin encapsulated in cationic liposomes.
    Gross N; Ranjbar M; Evers C; Hua J; Martin G; Schulze B; Michaelis U; Hansen LL; Agostini HT
    Mol Vis; 2013; 19():54-61. PubMed ID: 23335851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study.
    Miller JW; Schmidt-Erfurth U; Sickenberg M; Pournaras CJ; Laqua H; Barbazetto I; Zografos L; Piguet B; Donati G; Lane AM; Birngruber R; van den Berg H; Strong A; Manjuris U; Gray T; Fsadni M; Bressler NM; Gragoudas ES
    Arch Ophthalmol; 1999 Sep; 117(9):1161-73. PubMed ID: 10496388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Verteporfin inhibits growth of human glioma in vitro without light activation.
    Al-Moujahed A; Brodowska K; Stryjewski TP; Efstathiou NE; Vasilikos I; Cichy J; Miller JW; Gragoudas E; Vavvas DG
    Sci Rep; 2017 Aug; 7(1):7602. PubMed ID: 28790340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.
    Arch Ophthalmol; 1999 Oct; 117(10):1329-45. PubMed ID: 10532441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of the migration effect and molecular docking of verteporfin in different subtypes of breast cancer cells.
    Wei C; Li X
    Mol Med Rep; 2020 Nov; 22(5):3955-3961. PubMed ID: 32901856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study).
    Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
    Graefes Arch Clin Exp Ophthalmol; 2007 Sep; 245(9):1273-80. PubMed ID: 17333238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic study after submacular removal of choroidal neovascular membranes treated with verteporfin ocular photodynamic therapy.
    Moshfeghi DM; Kaiser PK; Grossniklaus HE; Sternberg P; Sears JE; Johnson MW; Ratliff N; Branco A; Blumenkranz MS; Lewis H
    Am J Ophthalmol; 2003 Mar; 135(3):343-50. PubMed ID: 12614752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3.
    Bressler NM; Arnold J; Benchaboune M; Blumenkranz MS; Fish GE; Gragoudas ES; Lewis H; Schmidt-Erfurth U; Slakter JS; Bressler SB; Manos K; Hao Y; Hayes L; Koester J; Reaves A; Strong HA;
    Arch Ophthalmol; 2002 Nov; 120(11):1443-54. PubMed ID: 12427056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Photodynamic therapy with verteporfin in a rabbit model of corneal neovascularization.
    Holzer MP; Solomon KD; Vroman DT; Sandoval HP; Margaron P; Kasper TJ; Crosson CE
    Invest Ophthalmol Vis Sci; 2003 Jul; 44(7):2954-8. PubMed ID: 12824237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study.
    Schmidt-Erfurth U; Miller JW; Sickenberg M; Laqua H; Barbazetto I; Gragoudas ES; Zografos L; Piguet B; Pournaras CJ; Donati G; Lane AM; Birngruber R; van den Berg H; Strong HA; Manjuris U; Gray T; Fsadni M; Bressler NM
    Arch Ophthalmol; 1999 Sep; 117(9):1177-87. PubMed ID: 10496389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guidelines for using verteporfin (visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes.
    ; ;
    Retina; 2002 Feb; 22(1):6-18. PubMed ID: 11884872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Verteporfin photodynamic therapy in the rat model of choroidal neovascularization: angiographic and histologic characterization.
    Zacks DN; Ezra E; Terada Y; Michaud N; Connolly E; Gragoudas ES; Miller JW
    Invest Ophthalmol Vis Sci; 2002 Jul; 43(7):2384-91. PubMed ID: 12091441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. YAP inhibitor verteporfin suppresses tumor angiogenesis and overcomes chemoresistance in esophageal squamous cell carcinoma.
    Wang XW; Zhao R; Yang ZY; Li T; Yang JC; Wang XL; Li XT; Zhao XR; Li XZ; Wang XX
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7703-7716. PubMed ID: 37000262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous but not prior inhibition of VEGF165 enhances the efficacy of photodynamic therapy in multiple models of ocular neovascularization.
    Ju M; Mailhos C; Bradley J; Dowie T; Ganley M; Cook G; Calias P; Lange N; Adamis AP; Shima DT; Robinson GS
    Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):662-70. PubMed ID: 18235012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factor VII-verteporfin for targeted photodynamic therapy in a rat model of choroidal neovascularization.
    Lu F; Hu Z; Sinard J; Garen A; Adelman RA
    Invest Ophthalmol Vis Sci; 2009 Aug; 50(8):3890-6. PubMed ID: 19357351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IQGAP1 causes choroidal neovascularization by sustaining VEGFR2-mediated Rac1 activation.
    Wang H; Ramshekar A; Kunz E; Sacks DB; Hartnett ME
    Angiogenesis; 2020 Nov; 23(4):685-698. PubMed ID: 32783108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.